Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies
Neoadjuvant chemoimmunotherapy (chemo-IO) has fundamentally reshaped the treatment paradigm for resectable non-small cell lung cancer (NSCLC), challenging long-held surgical boundaries and redefining what constitutes “resectable” disease. Trials such as CheckMate-816, KEYNOTE-671, and AEGEAN have de...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMJ Publishing Group
2026-02-01
|
| سلاسل: | Journal for ImmunoTherapy of Cancer |
| الوصول للمادة أونلاين: | https://jitc.bmj.com/content/14/2/e014098.full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|